Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 4,263 matching trials from the live ClinicalTrials.gov search.
Conditions
Immunity, Mucosal, Immune System Processes, Blood Specimen Collection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Not listed No phase listed Observational Accepts healthy volunteers

Neuroinflammation and Alzheimer's Pathology in POCD

NCT05378659
Conditions
Post-Operative Confusion, Neuroinflammatory Response, Alzheimer Disease
Interventions
Montreal Cognitive Assessment, Stroop Test, 4AT Delirium, Grooved Pegboard, NACC Cognitive Battery, ERP Testing, Blood Plasma and Serum sampling, Cerebral Spinal Fluid Sample
Behavioral · Diagnostic Test
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Cardiovascular Disease and Lipoprotein(a)
Interventions
Blood draw for Lp(a)
Diagnostic Test
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
180
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 150 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A

NCT02095288
Conditions
Healthy
Interventions
Blood draw
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Down Syndrome, Edwards Syndrome, Patau Syndrome, Klinefelter Syndrome, Turner Syndrome, DiGeorge Syndrome, Chromosome Deletion, Aneuploidy
Interventions
Blood sampling for Laboratory Developed Test (LDT) analysis
Other
Lead sponsor
Progenity, Inc.
Industry
Eligibility
18 Years to 54 Years · Female only
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Scottsdale, Arizona • Eunice, Louisiana • Brooklyn, New York + 5 more
Terminated No phase listed Observational Accepts healthy volunteers

Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels

NCT02771769
Conditions
Prostatic Neoplasms
Interventions
blood draw
Other
Lead sponsor
Chronix Biomedical Corporation
Industry
Eligibility
21 Years to 80 Years · Male only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Nashville, Tennessee
Recruiting No phase listed Observational Accepts healthy volunteers

Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple Sclerosis

NCT07878923
Conditions
Relapse Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Bone Marrow Diseases, Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 110 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Collection for COM/BSBS

NCT06082661
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more
Conditions
Metastatic Malignant Solid Neoplasm
Interventions
Bendamustine, Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, T-cell Receptor-engineered T-cells
Drug · Procedure · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Basal Cell Carcinoma, Squamous Cell Carcinoma
Interventions
Blood Draw
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Short course radiation, Active Surveillance
Radiation · Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Mantle Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib, Positron Emission Tomography and Computed Tomography Scan, Rituximab
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Conditions
Bladder Cancer
Interventions
Blood draw
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
New York, New York
Conditions
Advanced Malignant Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biospecimen Collection
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
143
States / cities
Fort Lauderdale, Florida • Savannah, Georgia • Honolulu, Hawaii + 89 more
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
intravenous fructose challenge, Blood Draw
Drug · Other
Lead sponsor
Manal F Abdelmalek
Other
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Healthy
Interventions
dolutegravir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Recruiting Phase 1 Interventional Accepts healthy volunteers

Positron Emission Tomography (PET) Imaging of Thrombosis

NCT03830320
Conditions
Atrial Fibrillation, COVID-19, Cancer, Thrombosis
Interventions
[64Cu]FBP8, PET/MR, Blood Collection, Electrocardiogram
Drug · Device · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting No phase listed Observational

OCS Heart Perfusion Post-Approval Registry

NCT05047068
Conditions
Transplant
Interventions
OCS Heart System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 20 more
Conditions
Sickle Cell Disease, Anemia, Anemia, Hemolytic, Anemia, Sickle Cell, Hematologic Diseases
Interventions
PROMIS for Pain Management App
Other
Lead sponsor
Julia Finkel
Other
Eligibility
8 Years to 21 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer

NCT00939510
Conditions
Prostate Cancer
Interventions
sargramostim, lenalidomide, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Robert Dreicer MD
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Terminated No phase listed Observational Accepts healthy volunteers

Extracellular RNA Markers of Liver Disease and Cancer

NCT02908048
Conditions
Hepatocellular Carcinoma, Biliary Tract Cancer, Cirrhosis, Liver Diseases
Interventions
Blood samples
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Chicago, Illinois • Rochester, Minnesota + 1 more